NCT07600463

Brief Summary

The LF-PODD study investigates the use of UVC (270nm) light in the prevention of surgical wound infections. Three devices are used in the study, two of which are actively producing UVC light (265 and 275 nm) and one device does not produce UVC light at all. The devices are outwardly completely identical and the devices are drawn for the research participants. Volunteers for neurosurgical procedures are selected for the study. Everyone participating in the study will be informed about the research and written consent will be requested. In the study, UVC light is focused on the surgical area at the beginning of the neurosurgical operation, during the operation, the device automatically dispenses UVC light into the air of the surgical area every 20 minutes, and at the end of the surgical procedure, the device delivers a single dose of UVC light to the surgical wound after closing the surgical wound. Study participants are monitored according to the standard treatment protocol and, in particular, the inflammation of the surgical wound is monitored. The results of the study are recorded and analysed using statistical methods.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for not_applicable

Timeline
44mo left

Started Jun 2026

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 25, 2024

Completed
1.6 years until next milestone

First Posted

Study publicly available on registry

May 20, 2026

Completed
15 days until next milestone

Study Start

First participant enrolled

June 4, 2026

Expected
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2028

1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2029

Last Updated

May 20, 2026

Status Verified

May 1, 2026

Enrollment Period

2.6 years

First QC Date

September 25, 2024

Last Update Submit

May 13, 2026

Conditions

Keywords

Surgical infectionPreventionUVC

Outcome Measures

Primary Outcomes (1)

  • The antimicrobial effects of UVC light in the edges of the surgical wound and nucleic acid detections

    The ability of UVC light to reduce the incidence of LHI pathogens in surgical wounds: The antimicrobial effects of UVC light are investigated from smear samples taken from the edges of the surgical wound and nucleic acid detections, from which live and dead microbes can be determined.

    *immediately after surgery

Secondary Outcomes (1)

  • Safety of UVC radiation

    immediately after surgery

Study Arms (3)

UVC active 265 nm

ACTIVE COMPARATOR

Active UVC light 265 nm

Device: UVC Irradiation

UVC sham

SHAM COMPARATOR

UVC sham

Device: UVC Irradiation

UVC active 275 nm

ACTIVE COMPARATOR

UVC active 275 nm

Device: UVC Irradiation

Interventions

UVC irradiation of surgical area

UVC active 265 nmUVC active 275 nmUVC sham

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • patients with idiopathic normal pressure hydrocephalus (iNPH) arriving for CSF shunt procedure
  • written informed consent

You may not qualify if:

  • immunosupressive medication
  • pregnancy
  • medication sensitizing for light exposure (e.g. doxycycline)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kuopio University Hospital

Kuopio, Puijonlaaksontie 2, 70210, Finland

Location

Related Publications (15)

  • Wilson AP, Treasure T, Sturridge MF, Gruneberg RN. A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis. Lancet. 1986 Feb 8;1(8476):311-3. doi: 10.1016/s0140-6736(86)90838-x.

    PMID: 2868173BACKGROUND
  • van Walraven C, Musselman R. The Surgical Site Infection Risk Score (SSIRS): A Model to Predict the Risk of Surgical Site Infections. PLoS One. 2013 Jun 27;8(6):e67167. doi: 10.1371/journal.pone.0067167. Print 2013.

    PMID: 23826224BACKGROUND
  • Dai T, Vrahas MS, Murray CK, Hamblin MR. Ultraviolet C irradiation: an alternative antimicrobial approach to localized infections? Expert Rev Anti Infect Ther. 2012 Feb;10(2):185-95. doi: 10.1586/eri.11.166.

    PMID: 22339192BACKGROUND
  • Sommer R, Haider T, Cabaj A, Heidenreich E, Kundi M. Increased inactivation of Saccharomyces cerevisiae by protraction of UV irradiation. Appl Environ Microbiol. 1996 Jun;62(6):1977-83. doi: 10.1128/aem.62.6.1977-1983.1996.

    PMID: 8787396BACKGROUND
  • Vonlanthen R, Slankamenac K, Breitenstein S, Puhan MA, Muller MK, Hahnloser D, Hauri D, Graf R, Clavien PA. The impact of complications on costs of major surgical procedures: a cost analysis of 1200 patients. Ann Surg. 2011 Dec;254(6):907-13. doi: 10.1097/SLA.0b013e31821d4a43.

    PMID: 21562405BACKGROUND
  • Thai TP, Keast DH, Campbell KE, Woodbury MG, Houghton PE. Effect of ultraviolet light C on bacterial colonization in chronic wounds. Ostomy Wound Manage. 2005 Oct;51(10):32-45.

    PMID: 16230765BACKGROUND
  • Ploegmakers IB, Olde Damink SW, Breukink SO. Alternatives to antibiotics for prevention of surgical infection. Br J Surg. 2017 Jan;104(2):e24-e33. doi: 10.1002/bjs.10426.

    PMID: 28121034BACKGROUND
  • McClelland S 3rd, Hall WA. Postoperative central nervous system infection: incidence and associated factors in 2111 neurosurgical procedures. Clin Infect Dis. 2007 Jul 1;45(1):55-9. doi: 10.1086/518580. Epub 2007 May 21.

    PMID: 17554701BACKGROUND
  • Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H. Light, including ultraviolet. J Autoimmun. 2010 May;34(3):J247-57. doi: 10.1016/j.jaut.2009.11.011. Epub 2009 Dec 16.

    PMID: 20018479BACKGROUND
  • Kimura H, Lee C, Hayashi K, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M, Hoffman RM. UV light killing efficacy of fluorescent protein-expressing cancer cells in vitro and in vivo. J Cell Biochem. 2010 Aug 15;110(6):1439-46. doi: 10.1002/jcb.22693.

    PMID: 20506255BACKGROUND
  • Kanerva M, Blom M, Tuominen U, Kolho E, Anttila VJ, Vaara M, Virolainen-Julkunen A, Lyytikainen O. Costs of an outbreak of meticillin-resistant Staphylococcus aureus. J Hosp Infect. 2007 May;66(1):22-8. doi: 10.1016/j.jhin.2007.02.014. Epub 2007 Apr 11.

    PMID: 17433492BACKGROUND
  • Hamidi-Oskouei AM, James C, James S. The Efficiency of UVC Radiation in the Inactivation of Listeria monocytogenes on Beef-Agar Food Models. Food Technol Biotechnol. 2015 Jun;53(2):231-236. doi: 10.17113/ftb.53.02.15.3966.

    PMID: 27904353BACKGROUND
  • Dai T, Kharkwal GB, Zhao J, St Denis TG, Wu Q, Xia Y, Huang L, Sharma SK, d'Enfert C, Hamblin MR. Ultraviolet-C light for treatment of Candida albicans burn infection in mice. Photochem Photobiol. 2011 Mar-Apr;87(2):342-9. doi: 10.1111/j.1751-1097.2011.00886.x. Epub 2011 Feb 10.

    PMID: 21208209BACKGROUND
  • Dai T, Garcia B, Murray CK, Vrahas MS, Hamblin MR. UVC light prophylaxis for cutaneous wound infections in mice. Antimicrob Agents Chemother. 2012 Jul;56(7):3841-8. doi: 10.1128/AAC.00161-12. Epub 2012 May 7.

    PMID: 22564833BACKGROUND
  • Abdullah KG, Attiah MA, Olsen AS, Richardson A, Lucas TH. Reducing surgical site infections following craniotomy: examination of the use of topical vancomycin. J Neurosurg. 2015 Dec;123(6):1600-4. doi: 10.3171/2014.12.JNS142092. Epub 2015 Jun 19.

    PMID: 26090835BACKGROUND

MeSH Terms

Conditions

Hydrocephalus

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System Diseases

Central Study Contacts

Ville Leinonen, Professor

CONTACT

Paula Walle, MD PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Randomization 1:1:1 into active UVC 265 nm, active UVC 275 nm and sham.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 25, 2024

First Posted

May 20, 2026

Study Start (Estimated)

June 4, 2026

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

December 31, 2029

Last Updated

May 20, 2026

Record last verified: 2026-05

Locations